Integration of novel targeted therapies into the systemic treatment of breast cancer - A review

Journal of B.U.ON.

Volumn 12, Issue 3, 2007, Pages 319-327

  Tsakonas, G ^a   Kosmas, Christos ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Bevacizumab; Breast cancer; Chemotherapy; Lapatinib; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PAZOPANIB; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE OVEREXPRESSION; HIGH RISK PATIENT; HUMAN; INFLAMMATORY DISEASE; LOADING DRUG DOSE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY; TREATMENT DURATION;

ANGIOGENESIS INHIBITORS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 35248894769     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Clark GM. Prognostic and predictive factors. In: Harris JR, Lippman ME, Morrow M et al. [Eds]: Diseases of the Breast. Philadelphia, PA, Lippincott- Raven Publishers, 1996, pp 461-485.
2. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
3. Levine MN, Bramwell V, Pritchard K et al. A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. Eur J Cancer 1992; 29: 37-43.
4. Levine MN, Bramwell VH, Pritchard KI et al. A randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node positive breast cancer. J Clin Oncol 1998; 16: 2651-2658.
5. Levine MN, Pritchard KI, Bramwell VH, Shepherd L, Tu D, Paul N. A randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of the National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005; 23: 5166-5170.
6. Pritchard KI, Shepherd LE, O'Malley FP et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 354: 2103-2111.
7. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: Are we at the end of the beginning? Clin Breast Cancer 2003; 4: 179-186.
8. Cardoso F, Durbecq V, Larsimont D et al. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/ metastatic breast cancer. Int J Oncol 2004; 24: 201-209.
9. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004; 39: 288-297.
10. Jarvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase II alpha associate with ErbB-2 amplification and affect sensitivity to the topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156: 839-847.
11. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999; 26: 142-150.
12. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase II alpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-1116.
13. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-7490.
14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
15. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
16. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
17. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
18. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-1070.
19. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
20. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006; 11: 318-324.
21. Rusnak DW, Lackey K, Affleck K et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
22. Baselga J, Carbonell X, Castañeda-Soto NJ et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-2171.
23. Osoba D, Slamon DJ, Burchmore M, Murphy M. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20: 3106-3113.
24. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
25. Romond EH, Perez EA. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
26. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 94 (Suppl 1): S5 (abstr).
27. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
28. Wigler N, O'Brien M, Rosso R et al. Reduced cardiac toxicity and comparable efficacy in a phase IlI trial of pegylated liposomal doxorubicin (Caelyx/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21: 45a (abstr).
29. Chia S, Clemons M, Martin LA et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 2006; 24: 2773-2778.
30. Karabelis A, Kosmas C, Mylonakis N et al. Paclitaxel (P), pegylated liposomal doxorubicin (PLD) and trastuzumab as 1st-line chemotherapy (chemo) in HER2/neu-positive (+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006; 24: 18S (abstr).
31. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
32. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
33. Moy B, Goss PE. Lapatinib: current status and future directions in breast cancer. Oncologist 2006; 11: 1047-1057.
34. Spector NL, Blackwell K, Hurley J et al. EGF 103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. J Clin Oncol 2006; 24 (18 Suppl): 3s, 502 (abstr).
35. Paoletti R GSK Oncology: Bringing Promise to Patients. Available at http:/www.gsk.com/investors/presentations/oncology2005/late-bw.pdf. Accessed October 25, 2006.
36. Christofanilli M, Boussen H, Baselga J et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). 29th Annu San Antonio Breast Cancer Symp, San Antonio, Texas 2006 (abstr 1).
37. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Cell Physiol 2001; 280: 1358-1366.
38. Sledge GW Jr. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002; 29: 104-110.
39. Brem SS, Gullino PM, Medina D. Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977; 195: 880-882.
40. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and their relation to angiogenesis. Cancer Res 1997; 57: 963-969.
41. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61: 5407-5414.
42. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
43. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550.
44. Sweeney CJ, Miller KD, Sissons SE et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001; 61: 3369-3372.
45. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
46. Miller KD, Wang M, Gralow J et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94 (Suppl 1): S6 (abstr).
47. Wedam SB, Low JA, Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-777.
48. Overmoyer B, Silverman P, Leeming R et al. Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cancer. Breast Cancer Res Treat 2004; 88 (Suppl): S106 (abstr).
49. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
50. Pegram M, Yeon C, Ku NC, Gaudreault J, Slamon DJ. Phase I combined biological therapy of breast cancer using two humanized monoclonal antibodies directed against HER2 protooncogene and vascular endothelial growth factor (VEGF). Breast Cancer Res Treat 2004; 88 (Suppl): S124 (abstr).
51. Miller KD, Burstein HJ, Elias AD et al. Phase II study of SU 11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2005; 23 (Suppl 1): 16S (abstr).
52. Moreno-Aspitia A, Hillman DW, Wiesenfeld M et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. Proc Am Soc Clin Oncol 2006; 24 (Suppl): 18S (abstr).